Home > Inhibitors & Agonists > Tyrosine Kinase > c-Met (HGFR)
Cat. No. Product name CAS No.
DC12007 SOMG-833

A potent, selective, ATP-competitive c-MET inhibitor with IC50 of 0.93 nM.

1268264-10-3
DC7056 AMG-208

AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM.

1002304-34-8
DC8845 AMG337 Featured

AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.

1173699-31-4
DC8515 BMS-2

BMS-2 is a potent MET kinase inhibitor with an IC50 value of 1.8nM. It also possesses potent inhibitory activity against Flt-3 and VEGFR-2 kinases, IC50 values of 4nM and 27nM respectively.

888719-03-7
DC9638 BMS-794833

BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7/15 nM; also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378.

1174046-72-0
DC5065 Golvatinib (E7050) Featured

E-7050 is hepatocyte growth factor receptors (HGFR).

928037-13-2
DC7408 Tepotinib(EMD-1214063) Featured

EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

1100598-32-0
DC7342 Foretinib(XL880)

Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR.

849217-64-7
DC11543 Glumetinib Featured

Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM.

1642581-63-2
DC7167 Capmatinib(INCB28060) Featured

INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase.

1029712-80-8
DC7177 JNJ 38877605

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.

943540-75-8
DC8479 MK-2461 Featured

MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB.

917879-39-1
DC7081 PF-04217903

PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).

956905-27-4
DC7230 PHA-665752

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM, >50-fold selectivity for c-Met than RTKs or STKs.

477575-56-7
DC7672 SAR125844 Featured

SAR125844 is inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity.

1116743-46-4
DC7294 SGX-523

SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α.

1022150-57-7
DC1093 SU11274 (PKI-SU11274) Featured

SU11274 is a selective Met inhibitor with IC50 of 10 nM.

658084-23-2
DC7065 Tivantinib (ARQ 197) Featured

Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4.

905854-02-6
DC7376 BMS777607 Featured

BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM.

1025720-94-8
DC28340 BPI-9016M

BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma.

1528546-94-2
DC28722 BAY-474 Featured

BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 acts as an epigenetics probe.

1033767-86-0
Page 1 / Total 1 FirstPrevNextLastGoto